101 results about "Hepatic lipid" patented technology

The invention relates to the technical field of biotechnology and gene function and application, and provides application of SNHG8 in preparation of drugs for preventing and treating non-alcoholic fatty liver diseases. The medicine is used for preventing and treating the non-alcoholic fatty liver disease by promoting SNHG8 gene expression. The SNHG8 is applied to preparation of the medicine for preventing and treating the non-alcoholic fatty liver disease, the medicine can effectively reduce the content of triglyceride in the liver by promoting SNHG8 gene expression, liver lipid accumulation increase and lipid metabolism related protein expression up-regulation induced by high-fat and high-cholesterol diet are relieved, and therefore the non-alcoholic fatty liver disease is prevented, treated or relieved. The purpose of preventing and treating the non-alcoholic fatty liver disease is achieved.

The invention discloses a Coprococcus eutaxus strain and an application of the Coprococcus eutaxus strain, and relates to the technical field of probiotics. According to the present invention, the Coprococcus eutactus strain is named as Coprococcus eutactus GZSY125, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, the preservation unit is Guangdong Microbial Culture Collection Center, and the address of the preservation unit is the fifth floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangdong Province, the preservation number is CGMCC No.66029, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, and the preservation number is CGMCC No.66029. The invention provides the Coprococcus eutaxus, the Coprococcus eutaxus can be used for remarkably improving liver lipid accumulation, inflammation and fibrosis, has a certain treatment effect on the metabolism-related fatty liver disease (MAFLD), provides a new treatment thought for clinically intervening the MAFLD, and has important clinical significance on the treatment of the MAFLD.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating glycolipid metabolic diseases and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15-19 parts of coptis chinensis, 10-15 parts of rhodiola rosea, 10-20 parts of gynostemma pentaphylla, 9-12 parts of kapok, 10-15 parts of soapberry, 9-15 parts of salvia miltiorrhiza, 10-15 parts of rhizoma alismatis, 9-12 parts of oriental wormwood, 9-12 parts of radix bupleuri, 5-10 parts of semen cassiae, 10-15 parts of rhizoma anemarrhenae, 10-15 parts of hawthorn, 6-9 parts of polygonum cuspidatum and 5-10 parts of fructus aurantii. The traditional Chinese medicine composition disclosed by the invention has the effects of inhibiting hyperlipidemia, hyperglycemia and hepatic lipid accumulation and relieving insulin resistance, and has a remarkable curative effect on relieving and treating glycolipid metabolic diseases.

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a duochin in preparation of a medicine for treating MASLD. The research finds that the eriochin has a positive effect on treatment of MASLD, and can effectively delay the body weight, liver weight and liver weight-body weight ratio of MASLD mice, relieve liver injury, relieve liver lipid deposition, liver fatty degeneration, inflammation and fibrosis and delay the MASLD disease progress. Research finds that the eriochin can effectively reduce body weight, relieve liver injury and relieve fatty degeneration and inflammation of the liver, so that MASLD is improved. The invention provides a new thought for the treatment research of MASLD.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The present invention discloses the application of the combined drug of mecobalamin (MeCbl) and Shuilinjia (SC) in the treatment of non-alcoholic steatohepatitis (NASH). The present invention firstly proposes that oral MeCbl can effectively intervene in and treat the progression of NASH disease, and firstly proposes that the combined drug of oral MeCbl and SC can synergistically enhance the treatment of NASH, as well as liver injury, inflammation, liver fibrosis and hepatic lipid deposition on the basis of monomeric drugs. The MeCbl / SC composition in the present invention has a potent effect on the treatment of NASH, provides a new therapeutic drug for such refractory liver diseases clinically, while reducing the single-drug use dose of SC, and reducing the incidence of adverse reactions and treatment costs of patients. The pharmacokinetics and safety data of the drug molecules involved in the present invention are relatively detailed, and the development of new indications can quickly enter clinical evaluation, saving development costs while shortening the R & D cycle.

The invention discloses an application of a SUMO agonist N106 (the molecular formula is C17H14N4O3S, and the molecular weight is 354.38) in treatment or prevention of metabolic dysfunction related fatty liver disease (MASLD). The early-stage research of the invention finds that the liver SUMOylation level in MASLD clinical specimens and animal models is significantly reduced. In-vivo experiments show that in a high-fat diet induced C57BL / 6 mouse model, N106 (10mg / kg, intraperitoneal injection, once a day) can significantly improve liver lipid deposition and blood fat level of a high-fat diet mouse; in in-vitro experiments, N106 (10 mu M for 24 hours) can effectively reduce lipid droplet accumulation of HepG2 cells. The research reveals that N106 regulates lipid metabolism by activating an SUMOylation modification pathway for the first time, and a novel treatment strategy is provided for MASLD.

This invention discloses the application of American ginseng glycoprotein extract in the preparation of drugs for treating alcoholic liver disease, belonging to the field of biomedical technology. This invention verifies that TD can significantly reduce serum ALT, AST, and TG levels in ALD mice, effectively reducing liver damage and lipid accumulation; inhibit NLRP3 protein expression and its downstream targets, effectively alleviating liver inflammation and pyroptosis; and improve intestinal flora imbalance in ALD mice. American ginseng glycoprotein extract has multi-target protective effects against alcoholic liver disease, reducing alcohol-induced liver tissue inflammation and oxidative stress damage. It has a mild composition and high safety profile, and can synergistically exert effects in liver protection, anti-inflammation, and antioxidation, making it suitable for adjunctive intervention and long-term management of alcoholic liver disease, providing a natural, mild, and effective protective pathway for alcoholic liver damage.

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

The present application relates to a new use of Fuling Gancao Decoction, and specifically discloses application of Fuling Gancao Decoction in treatment of hyperlipidemia, wherein the Fuling Gancao Decoction is composed of the following components in parts by weight: Fuling 2 parts, Guizhi 2 parts, Zhigancao 1 part and Shengjiang 3 parts. It is found through animal experiment research that the Fuling Gancao Decoction can improve the symptoms of hyperlipidemia rats, reduce the content of TG, TC and LDL-C in serum, improve the liver lipid, blood sugar of hyperlipidemia model animals, reduce the liver coefficient, improve the liver cell fatty degeneration, reverse the pathological morphology of adipose tissue cells and the mitochondrial damage of hyperlipidemia model animals. A new indication of the Fuling Gancao Decoction is found, the development of traditional Chinese medicines is promoted, and a new drug composition with less side effects is provided for treatment of hyperlipidemia.

This invention discloses a traditional Chinese medicine composition, preparation method, and application with lipid-lowering and intestinal flora-regulating effects, belonging to the field of traditional Chinese medicine technology. The raw material components are: 10-20 parts mulberry leaf, 10-20 parts immature bitter orange, 10-20 parts plantain, 8-15 parts lotus leaf, 8-16 parts medicated leaven, and 8-15 parts poria cocos. Based on the etiology and pathogenesis of obesity, this invention adopts a formula based on the principles of eliminating dampness and phlegm, lowering lipids and clearing turbidity. In addition to changing the obese phenotype, it focuses on balancing the body's internal organs and blood, strengthening the spleen and replenishing qi, resolving phlegm and eliminating dampness, supplemented by promoting qi circulation and digestion, lowering lipids and eliminating phlegm, thereby regulating the body's overall function, accelerating the decomposition of excess fat, and achieving the goal of weight loss by lowering lipids and regulating intestinal flora. Pharmacological experiments have shown that oral administration significantly improves weight gain and liver lipid accumulation induced by a high-fat diet in rats, resulting in clearer liver cord structure, denser cell arrangement, reduced lipid vacuolation and ballooning degeneration, and altering the composition and function of the intestinal microbiota.

The invention belongs to the technical field of functional microorganism application, and particularly relates to a novel lipid-lowering peptide derived from a probiotic thallus and application thereof, the novel lipid-lowering peptide is a crushed substance derived from a probiotic lactobacillus plantarum thallus, and the molecular weight of the novel lipid-lowering peptide is less than 3kDa. And two key polypeptides APGFGDR (AP7) and TESGAFGR (TE8) are identified from the components, and can specifically inhibit the activities of pancreatic lipase and pancreatic cholesterol esterase. The extracted thallus peptide can be efficiently combined with cholate to inhibit the formation of cholesterol micelles, and has a remarkable inhibiting effect on pancreatic lipase and pancreatic cholesterol esterase. Animal experiments show that the mycopeptide can effectively improve lipid metabolism disorder induced by high fat diet, inhibit weight gain, reduce serum and liver lipid levels and relieve fatty degeneration and inflammation of the liver. The lipid-lowering peptide disclosed by the invention is high in safety and multi-target in action, and can be used for preparing functional products for preventing or treating metabolic diseases such as obesity, hyperlipidemia and the like.

The invention relates to an anti-inflammatory and lipid-lowering-based nano preparation for treating fatty liver and a preparation method of the nano preparation. Galactose modified polyethylene glycol-polylactic acid-glycolic acid copolymer (PEG-PLGA) is used as a targeting carrier, and a lipid-lowering drug fenofibrate and an anti-inflammatory drug curcumin are co-loaded; the particle size of the nano preparation is 150-200nm, and the drug encapsulation efficiency is greater than or equal to 85%. Galactose modified PEG-PLGA is adopted as a carrier, galactose can be specifically combined with an asialoglycoprotein receptor (ASGPR) specifically expressed on the surface of liver cells, active targeting of the liver is achieved, the drug enrichment amount of the liver lesion position is remarkably increased, meanwhile, accumulation of drugs in extrahepatic tissue is reduced, extrahepatic toxicity is effectively reduced, and the drug delivery effect is improved. According to the present invention, the anti-inflammatory drug curcumin and the fenofibrate are combined, such that the biological safety of the preparation is improved, the lipid lowering drug fenofibrate and the anti-inflammatory drug curcumin are innovatively co-loaded, and the fenofibrate and the anti-inflammatory drug curcumin form the synergistic effect system: fenofibrate can activate peroxisome proliferator-activated receptor alpha (PPAR alpha), promote liver lipid catabolism, and reduce lipid deposition;

The present application relates to the field of biomedicine technology, and in particular to the use of cinnamoylglycine in the preparation of products for predicting or preventing metabolic-related fatty liver disease. The present invention is based on the use of cinnamoylglycine to prevent and / or treat metabolic-related fatty liver disease and its related conditions. Experimental results show that: cinnamoylglycine can effectively predict the risk of metabolic-related fatty liver disease and high-risk metabolic-related fatty liver hepatitis in community populations; cinnamoylglycine intervention can effectively reduce the body weight, triglyceride and cholesterol levels of mice induced by a high-fat and high-cholesterol diet, and improve liver lipid deposition, inflammatory cell infiltration and hepatocyte ballooning; cinnamoylglycine improves metabolic-related fatty liver disease by inhibiting the expression and activity of FDPS. The present invention provides new and effective intervention ideas and means for metabolic-related fatty liver disease and its related conditions.

This invention discloses the use of the SLC7A5 gene or its encoded product as a target in the preparation of drugs for the prevention and / or treatment of metabolic dysfunction-related fatty liver disease (MASLD). This invention reveals for the first time that SLC7A5 is a key node regulating hepatic lipid metabolism, and inhibiting its expression or function can significantly reduce hepatic steatosis, inflammation, and fibrosis. Specifically, this invention relates to pharmaceutical compositions containing SLC7A5 inhibitors, said inhibitors including small molecule compounds, specific antibodies, nucleic acid interfering agents, or gene editing tools. Furthermore, this invention provides a drug screening method for MASLD, which combines molecular docking virtual screening technology with target specificity verification steps, and the application of SLC7A5 as a biomarker in disease diagnosis, staging, and efficacy monitoring. This invention provides definite new targets and candidate drugs with well-defined mechanisms for the clinical diagnosis and treatment of MASLD.

The invention belongs to the technical field of biological medicine, and particularly relates to application of recombinant Glypican 1 protein in treatment of non-alcoholic steatohepatitis. The Glypican 1 protein can treat non-alcoholic steatohepatitis for the first time, experiments prove that the Glypican 1 protein can improve liver lipid deposition, inflammation, fibrosis and other key pathological characteristics, and particularly, after the serum GPC1 level is increased, the Glypican 1 protein can inhibit high-fat and high-cholesterol diet induced mouse body weight increase, optimize the ratio of liver tissue weight to body weight, and improve the non-alcoholic steatohepatitis. The glucose tolerance and the insulin sensitivity are improved, so that the metabolic disorder is integrally improved; besides, the GPC1 accelerant can directly target macrophages, inhibit expression of pro-inflammatory genes (such as Tnf and Nos2) and relieve cascade reaction of liver inflammation, the anti-inflammatory effect is achieved by inhibiting an ERK1 / 2 phosphorylation pathway in mechanism, an innovative, efficient and flexible solution is provided for NASH treatment on the whole, and the defects of current treatment means are overcome.

The invention discloses an application of clofampol in preparation of a medicine for preventing and / or treating non-alcoholic fatty liver disease, and belongs to the technical field of medicines. It is found that the clofamprol can reduce the liver index, effectively improve liver lipid metabolism disorder, inhibit hepatic cell fatty degeneration, inflammatory response and fibrosis processes, reduce the level of alanine transaminase, aspartic transaminase, total bilirubin, triglyceride and low-density lipoprotein, improve the level of albumin and high-density lipoprotein, and inhibit liver cell fatty degeneration, inflammatory response and fibrosis processes. Therefore, effective treatment on the non-alcoholic fatty liver is realized.

The invention discloses a traditional Chinese medicine composition, belongs to the technical field of traditional Chinese medicines, and aims to solve the problems of dyslipidemia and liver lipid deposition caused by chronic high fat diet. The composition comprises two formulas, wherein the formula A consists of astragalus membranaceus, lucid ganoderma and schisandra chinensis according to the weight ratio of 1: 1: 1; the formula B is composed of schisandra chinensis and liquorice according to the weight ratio of 3: 1, and can significantly activate an NRF2 / ARE pathway, up-regulate expression of antioxidant genes such as NQO1 and HO-1, inhibit H2O2-induced ROS generation and cell apoptosis, and improve related symptoms from the molecular level; meanwhile, the provided preparation method can improve the solubility of active ingredients and the intestinal absorption efficiency, avoids ingredient degradation caused by high-temperature extraction, ensures long-acting stable release of the medicine in vivo, and is mainly used for improving dyslipidemia and liver lipid deposition caused by chronic high-fat diet.

The invention discloses application of intestinal flora metabolite reuterin in preparation of a medicine for relieving or treating atherosclerosis, and relates to the technical field of medicine. The reuterin can reduce the blood sugar level, the total cholesterol level and the low-density lipoprotein cholesterol level, reduce liver lipid deposition, improve liver fatty degeneration, promote growth of beneficial bacteria, inhibit proliferation of potential harmful bacteria and inhibit cell penetration and uptake of low-density lipoprotein in endothelial cells. According to the application, the fact that the reuterin can be used for relieving or treating the atherosclerosis is disclosed for the first time, a new direction is provided for treating the atherosclerosis, and experiments show that the reuterin does not cause adverse effects on liver and kidney functions of mice after being used for a long time, and shows that the reuterin has good biological safety.

The invention discloses an application of a traditional Chinese medicine composition in preparation of a medicine for preventing or treating acute and chronic liver diseases, and relates to the technical field of medicines, the application is the application of the traditional Chinese medicine composition in preparation of the medicine for preventing or treating acute and chronic liver diseases, and the traditional Chinese medicine composition is prepared from red ginseng, fructus aurantii and rabdosia amethystoides. Experiments find that the traditional Chinese medicine composition can significantly improve liver lipid accumulation, reduce the level of inflammatory factors of inflammatory cells and improve liver fibrosis indexes, and the effect is superior to that of a positive drug rosimeltirol; acute liver injury induced by ethanol is improved; the traditional Chinese medicine composition can improve the activity of LPL, enhance lipid metabolism and reduce blood fat, so that the effect of preventing or treating acute and chronic liver diseases is achieved, and the clinical application value of the traditional Chinese medicine composition is expanded.

The invention discloses an application of a jerusalem artichoke tuber alcohol extract in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the technical field of medicines, the chemical components of the jerusalem artichoke tuber alcohol extract are mainly flavonoid substances, and the jerusalem artichoke tuber alcohol extract can remarkably recover the weight of a mouse with the type 2 diabetes mellitus and improve glucose metabolism indexes such as fasting blood-glucose and oral glucose tolerance; meanwhile, insulin sensitivity is stimulated to secrete insulin, and the functions of pancreatic beta cells are recovered; in addition, the concentration of biochemical indexes such as total cholesterol and triglyceride in the liver is reduced, lipid metabolism of the liver is improved, and a new direction is provided for research and development of natural plant source hypoglycemic products.

The invention discloses a traditional Chinese medicine composition for treating metabolism-related fatty liver diseases and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition is prepared from 30 g of poria cocos, 30 g of rhizoma atractylodis macrocephalae, 30 g of radix salviae miltiorrhizae, 10 g of fructus crataegi, 15 g of pericarpium citri reticulatae, 15 g of lotus leaves, 10 g of rhizoma alismatis, 15 g of red yeast rice, 10 g of herba artemisiae scopariae and 10 g of emblic leafflower fruit according to The freeze-dried powder is prepared by adopting processes of three times of water extraction, low-temperature vacuum concentration and freeze drying, the extraction efficiency is about 37%, and active ingredients are completely reserved. Animal experiments show that the composition can significantly relieve obesity, improve liver fatty degeneration, reduce liver lipid deposition, repair liver injury, regulate dyslipidemia, improve glucose tolerance and insulin resistance, and inhibit liver lipid synthesis and inflammatory response; and no liver and kidney toxicity is caused by continuous high-dose use. The composition provided by the invention has the advantages of multiple targets, systematic regulation of metabolism, exact curative effect and high safety, and provides a novel effective traditional Chinese medicine scheme for prevention and treatment of metabolism-related fatty liver diseases.

The invention relates to the technical field of traditional Chinese medicine preparations, and discloses a salvia miltiorrhiza salvianolic acid and notoginsenoside composition, and the mass ratio of notoginsenoside to salvianolic acid in the composition is 1: 5 or 5: 3 or 3: 5. The invention further discloses application of the composition in preparation of drugs for preventing and treating vasculopathy related to metabolic syndromes of metabolic organs. The composition disclosed by the invention can be used for remarkably relieving liver lipid deposition induced by high-fat diet and reducing abnormal accumulation of white and beige fat; wherein the optimal compatibility ratio is 1: 5, and the mechanism of playing the role is related to down-regulation of the expression of liver lipid transport key protein CD36; the invention provides a new intervention strategy and compatibility basis for preventing and treating vasculopathy related to metabolic syndrome, and provides a precise intervention thought of'combining diseases and syndromes' for the research of early prevention of atherosclerosis.

This invention discloses a probiotic protein V2016 and its application in the preparation of drugs for treating obesity, belonging to the field of biomedical technology. This invention provides a probiotic protein V2016, the amino acid sequence of which is shown in SEQ ID NO.1. Verification has shown that protein V2016 can efficiently and stably bind to the intestinal receptor ICAM-2, thereby significantly upregulating GLP-1 expression, mediating weight loss, reduced fat accumulation, and improved glucose tolerance; simultaneously, it can also reduce hepatic lipid deposition and inflammation, and promote thermogenesis activation in adipose tissue; at the intestinal microecological level, protein V2016 can improve the intestinal microenvironment, promote the enrichment of butyrate-producing bacteria in the intestine, thereby playing a role in regulating metabolism. In summary, the protein V2016 provided by this invention can be applied to the development of novel functional foods or weight-loss drugs.

The invention relates to the technical field of biological medicines, in particular to polypeptide for treating non-alcoholic fatty liver diseases. The invention provides a novel octapeptide P3-1 (SEQ ID NO: 1) derived from macadamia nuts. The novel octapeptide P3-1 (SEQ ID NO: 1) can remarkably improve liver lipid metabolism disorder, restore liver functions, relieve inflammatory response and increase abundance of probiotics in mice with non-alcoholic fatty liver diseases induced by high fat diet. The polypeptide is small in molecular weight, safe in source and easy to absorb, has good medicinal and health-care food development potential, and provides a safe and effective new way for targeted intervention of the non-alcoholic fatty liver disease.

The invention relates to a lactobacillus paracasei K56 metagen and application of the lactobacillus paracasei K56 metagen in the aspect of controlling in-vivo fat, and particularly provides one or more applications of the lactobacillus paracasei K56 metagen selected from the group consisting of the following beneficial intestinal bacteria: the lactobacillus paracasei K56 metagen is used for promoting the proliferation of the beneficial intestinal bacteria, the beneficial intestinal bacteria are selected from one or more of norkfRuminococcus, Lactobacillus and Coriobacterium UCG-002, preferably one or more of norkfRuminococcus and Coriobacterium UCG-002, and the lactobacillus paracasei K56 metagen is used for promoting the proliferation of the beneficial intestinal bacteria, preferably one or more of the norkfRuminococcus, Lactobacillus and Coriobacterium UCG-002. The composition is used for regulating obesity (such as obesity caused by high-fat diet); for modulating (e.g., caused by high fat diet) lipid metabolism disorders and / or liver lipid accumulation; for modulating (e.g., caused by high fat diet) colon immune disorders; wherein the lactobacillus paracasei K56 is preserved in the German Colletion of Microorganisms and Cell Cultures, the preservation number of the lactobacillus paracasei K56 is DSM 27447, and the lactobacillus paracasei K56 is preserved in the German Microorganism Preservation Center (MCC), the preservation number of the lactobacillus paracasei K56 is DSM 27447, and the preservation number of the lactobacillus paracasei K56 is CGMCC NO. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number of the strain is CGMCC 15139, and the strain is also preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the strain is CGMCC 15139.

The invention specifically discloses application of RNA binding protein FXR1 as a target spot in preparation of products for preventing and treating metabolism-related fatty liver diseases and improving glucose and lipid metabolism disorders, and relates to the technical field of biological medicines. By constructing a liver specific knockout mouse (HKO) and high-fat and high-sugar diet induction model, the invention reveals that the RNA binding protein FXR1 is a key pathogenic factor for liver fatty degeneration and metabolic disorder for the first time, and discovers that the deletion of the RNA binding protein FXR1 can significantly improve liver lipid deposition, alleviate liver injury and fibrosis, and can be used for treating liver fatty degeneration and metabolic disorder. The invention can improve the abnormal glucose tolerance and insulin resistance of the whole body, and inhibit the RNA binding protein FXR1 as a new strategy for treating liver glycolipid metabolism and metabolism-related fatty liver diseases.

The present invention relates to a composition for regulating hepatic lipid metabolism, comprising Lactiplantibacillus plantarum OPT-A1 strain deposited under accession number KCTC 15555BP, a culture liquid thereof, a cultured product thereof, or a culture lysate thereof. The composition suppresses lipid accumulation and expression of genes related to lipogenesis in hepatocytes, and enhances expression of genes related to lipid oxidation. In addition, the composition inhibits accumulation of triglycerides in hepatocytes and reduces blood triglyceride levels, total cholesterol levels, and liver injury indices. Furthermore, the composition promotes rapid consumption of lipids in hepatocytes and somatic cells through enhancement of muscle mass, and thus can be advantageously used as a raw material for foods, pharmaceuticals, and the like related to alleviation and treatment of various metabolic diseases.